SUMMIT, N.J.--(BUSINESS WIRE)-- 2007 Third Quarter Financial Results Year-Over-Year: Total Revenue Increased 43 Percent to $350 Million Product Sales Increased 48 Percent to $331 Million REVLIMID® Net Product Sales Increased 97 Percent to $199 Million THALOMID® Net Product Sales Increased to $111 Million Adjusted Operating Income Increased 84 Percent to $146 Million Adjusted Net Income Increased 109 Percent to $124 Million Adjusted Earnings Per Share Increased 93 Percent to $0.29 Per Diluted Share
